CR20200487A - Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos - Google Patents
Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estosInfo
- Publication number
- CR20200487A CR20200487A CR20200487A CR20200487A CR20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A
- Authority
- CR
- Costa Rica
- Prior art keywords
- peptide
- tyrosine
- glp
- glucagon
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico. La invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas. Los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862662313P | 2018-04-25 | 2018-04-25 | |
US2018029284 | 2018-04-25 | ||
PCT/IB2019/053384 WO2019207505A1 (en) | 2018-04-25 | 2019-04-24 | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200487A true CR20200487A (es) | 2021-03-11 |
Family
ID=66676857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200487A CR20200487A (es) | 2018-04-25 | 2019-04-24 | Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP3784692A1 (es) |
JP (1) | JP2021522258A (es) |
KR (1) | KR20210005674A (es) |
CN (1) | CN112004822A (es) |
AU (2) | AU2019259790B2 (es) |
BR (1) | BR112020021562A2 (es) |
CA (1) | CA3096792A1 (es) |
CL (1) | CL2020002718A1 (es) |
CO (1) | CO2020013221A2 (es) |
CR (1) | CR20200487A (es) |
DO (1) | DOP2020000192A (es) |
EC (1) | ECSP20067968A (es) |
IL (1) | IL278197A (es) |
JO (1) | JOP20200265A1 (es) |
MA (1) | MA52361A (es) |
MX (1) | MX2020011293A (es) |
NI (1) | NI202000071A (es) |
PE (1) | PE20211457A1 (es) |
PH (1) | PH12020551659A1 (es) |
SA (1) | SA520420401B1 (es) |
SG (1) | SG11202009844SA (es) |
UY (1) | UY38200A (es) |
WO (1) | WO2019207505A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190097A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
AU2022429854A1 (en) * | 2021-12-31 | 2024-07-04 | Sunshine Lake Pharma Co., Ltd. | Fusion protein of glp-1 and gdf15 and use thereof |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN117327200B (zh) * | 2023-11-28 | 2024-02-09 | 西宝生物科技(上海)股份有限公司 | 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2422807A3 (en) * | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
BRPI0507585A (pt) * | 2004-03-17 | 2007-07-03 | 7Tm Pharmas As | agonistas seletivos do receptor y2 para intervenções terapêuticas |
CN101128487B (zh) * | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
BRPI0615538A2 (pt) * | 2005-07-29 | 2011-05-17 | Amprotein Corp | proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição farmacêutica, composição alimentar, método para a redução do peso corpóreo, método para o tratamento de diabetes, método para aumentar a vida média de um peptìdio ou uma proteìna terapêutica recombinante em um indivìduo, método para aumentar a eficácia de um peptìdio ou proteìna terapêutica, método para o tratamento de diabetes ou redução do peso corpóreo |
JP2009504681A (ja) * | 2005-08-11 | 2009-02-05 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 選択可能な特性を有するハイブリッドポリペプチド |
JP5399244B2 (ja) * | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
AU2010303112A1 (en) * | 2009-09-30 | 2012-04-26 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
AU2016343775B2 (en) * | 2015-10-28 | 2021-07-29 | Tufts Medical Center | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
-
2019
- 2019-04-24 EP EP19727508.4A patent/EP3784692A1/en active Pending
- 2019-04-24 MX MX2020011293A patent/MX2020011293A/es unknown
- 2019-04-24 PE PE2020001671A patent/PE20211457A1/es unknown
- 2019-04-24 BR BR112020021562-7A patent/BR112020021562A2/pt unknown
- 2019-04-24 CA CA3096792A patent/CA3096792A1/en active Pending
- 2019-04-24 WO PCT/IB2019/053384 patent/WO2019207505A1/en active Application Filing
- 2019-04-24 MA MA052361A patent/MA52361A/fr unknown
- 2019-04-24 AU AU2019259790A patent/AU2019259790B2/en active Active
- 2019-04-24 KR KR1020207033769A patent/KR20210005674A/ko not_active Application Discontinuation
- 2019-04-24 CN CN201980028055.4A patent/CN112004822A/zh active Pending
- 2019-04-24 CR CR20200487A patent/CR20200487A/es unknown
- 2019-04-24 SG SG11202009844SA patent/SG11202009844SA/en unknown
- 2019-04-24 JP JP2020559562A patent/JP2021522258A/ja active Pending
- 2019-04-24 JO JOP/2020/0265A patent/JOP20200265A1/ar unknown
- 2019-04-25 UY UY38200A patent/UY38200A/es unknown
-
2020
- 2020-10-04 PH PH12020551659A patent/PH12020551659A1/en unknown
- 2020-10-20 CL CL2020002718A patent/CL2020002718A1/es unknown
- 2020-10-21 IL IL278197A patent/IL278197A/en unknown
- 2020-10-22 SA SA520420401A patent/SA520420401B1/ar unknown
- 2020-10-22 CO CONC2020/0013221A patent/CO2020013221A2/es unknown
- 2020-10-22 NI NI202000071A patent/NI202000071A/es unknown
- 2020-10-23 EC ECSENADI202067968A patent/ECSP20067968A/es unknown
- 2020-10-23 DO DO2020000192A patent/DOP2020000192A/es unknown
-
2023
- 2023-11-29 AU AU2023274117A patent/AU2023274117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202014433A (zh) | 2020-04-16 |
NI202000071A (es) | 2021-01-21 |
JP2021522258A (ja) | 2021-08-30 |
AU2019259790A1 (en) | 2020-10-22 |
CN112004822A (zh) | 2020-11-27 |
CL2020002718A1 (es) | 2021-01-29 |
ECSP20067968A (es) | 2020-11-30 |
CA3096792A1 (en) | 2019-10-31 |
BR112020021562A2 (pt) | 2021-03-02 |
IL278197A (en) | 2020-11-30 |
PH12020551659A1 (en) | 2021-07-26 |
MA52361A (fr) | 2021-03-03 |
AU2019259790B2 (en) | 2023-08-31 |
PE20211457A1 (es) | 2021-08-05 |
WO2019207505A1 (en) | 2019-10-31 |
AU2023274117A1 (en) | 2023-12-21 |
EP3784692A1 (en) | 2021-03-03 |
DOP2020000192A (es) | 2021-04-30 |
SG11202009844SA (en) | 2020-11-27 |
CO2020013221A2 (es) | 2020-11-10 |
JOP20200265A1 (ar) | 2020-10-21 |
UY38200A (es) | 2019-10-31 |
MX2020011293A (es) | 2020-11-13 |
KR20210005674A (ko) | 2021-01-14 |
SA520420401B1 (ar) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20200487A (es) | Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos | |
PH12019500749A1 (en) | Antibody-coupled cyclic peptide tyrosine compounds as modulators of neuropeptide y receptors | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2019001319A (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
MX2017007458A (es) | Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos. | |
PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
PH12021550964A1 (en) | Protein tyrosine-tyrosine analogs and methods of using the same. | |
PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
NO20080552L (no) | GLP-1 farmasoytiske sammensetninger | |
PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
MX2022003243A (es) | Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos. | |
TN2021000076A1 (en) | Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof | |
AR114291A1 (es) | Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos | |
EA202092547A1 (ru) | Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение | |
IL277024A (en) | ", 5"-dimethoxybenzoyl-3'-amino-3'-deoxyadenosine-5'-triphosphates and their pharmaceutical uses | |
WO2019232415A8 (en) | Bacteria engineered to treat liver disease | |
AU2019253577A1 (en) | Oxytocin compositions and methods of use | |
CR20220046A (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 | |
MX2022006743A (es) | Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo. | |
MX2020012486A (es) | Composicion de inmunoglobulinas humanas concentradas. |